Loading…
Lobbying Spend
—
Filings
240
Firms Hired
6
Active Period
1999–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Inflation Reduction Act of 2022
2022 · fourth_quarter · Firm: THORN RUN PARTNERS
Issues related to Medicare and Medicaid reimbursement for pharmaceuticals. Medicare reimbursement for biosimilars. Issues related to biosimilar therapies. Issues related to Part D formularies. Prescription Drug User Fee Act (PDUFA). H.R.5376 - Inflation Reduction Act of 2022.
Client expense: — · Firm income: $50,000
Matched citations: H.R.5376
Inflation Reduction Act of 2022
2022 · third_quarter · Firm: THORN RUN PARTNERS
Issues related to Medicare and Medicaid reimbursement for pharmaceuticals. Medicare reimbursement for biosimilars. Issues related to biosimilar therapies. Issues related to Part D formularies. Prescription Drug User Fee Act (PDUFA). H.R.5376 - Inflation Reduction Act of 2022.
Client expense: — · Firm income: $50,000
Matched citations: H.R.5376
Issues related to the Biologics Price Competition and Innovation Act of 2009. Issues related to FDA user fee legislation, including S. 4348, the Food and Drug Administration Safety and Landmark Advancements Act of 2022.
Client expense: — · Firm income: $50,000
Matched citations: S. 4348
Lowering Costs by Improving Biosimilar Uptake Act
2022 · second_quarter · Firm: KING & SPALDING LLP
H.R. 7047, Lowering Costs by Improving Biosimilar Uptake Act
Client expense: — · Firm income: $10,000
Matched citations: H.R. 7047
Issues related to the Biologics Price Competition and Innovation Act of 2009. Issues related to FDA user fee legislation, including S. 4348, the Food and Drug Administration Safety and Landmark Advancements Act of 2022.
Client expense: — · Firm income: $50,000
Matched citations: S. 4348
Lowering Costs by Improving Biosimilar Uptake Act
2022 · first_quarter · Firm: KING & SPALDING LLP
H.R. 7047, Lowering Costs by Improving Biosimilar Uptake Act
Client expense: — · Firm income: $10,000
Matched citations: H.R. 7047
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021
2020 · third_quarter · Firm: THORN RUN PARTNERS
Issues related to supply chain policy. Issues related to ICD-10 Coding for Breakthrough Therapy Designations; H.R.7614 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021
Client expense: — · Firm income: $50,000
Matched citations: H.R.7614
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021
2020 · second_quarter · Firm: THORN RUN PARTNERS
Issues related to supply chain policy. Issues related to access to diabetes medicines; issues related to ICD-10 Coding for Breakthrough Therapy Designations; H.R.7614 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021
Client expense: — · Firm income: $50,000
Matched citations: H.R.7614
Foreign Investment Risk Review Modernization Act of 2017
2018 · second_quarter · Firm: THORN RUN PARTNERS
Legislation related to CFIUS and FARA including issues related to critical technologies and export controls; S.2098/H.R.4311, Foreign Investment Risk Review Modernization Act of 2017; S.2482, Foreign Agents Registration Amendments Act of 2018.
Client expense: — · Firm income: $50,000
Matched citations: H.R.4311
Foreign Investment Risk Review Modernization Act of 2018
2018 · second_quarter · Firm: THORN RUN PARTNERS
Legislation related to CFIUS and FARA including issues related to critical technologies and export controls; S.2098/H.R.4311, Foreign Investment Risk Review Modernization Act of 2017; S.2482, Foreign Agents Registration Amendments Act of 2018.
Client expense: — · Firm income: $50,000
Matched citations: S.2098
Foreign Agents Registration Amendments Act of 2018
2018 · second_quarter · Firm: THORN RUN PARTNERS
Legislation related to CFIUS and FARA including issues related to critical technologies and export controls; S.2098/H.R.4311, Foreign Investment Risk Review Modernization Act of 2017; S.2482, Foreign Agents Registration Amendments Act of 2018.
Client expense: — · Firm income: $50,000
Matched citations: S.2482
Consolidated Appropriations Act, 2018
2018 · first_quarter · Firm: THORN RUN PARTNERS
Rebates for dual eligible and low-income subsidy population in Medicare Part D. Non-Interference. Implementation of the 21st Century Cures Act (P.L.114-255). ADUFA Reauthorization. Part D coverage gap and the Medicare reimbursement of biosimilars; H.R.1892, Bipartisan Budget Act of 2018 (P.L.115-123); H.R.1625, Consolidated Appropriations Act, 2018 (P.L.115-141).
Client expense: — · Firm income: $50,000
Matched citations: H.R.1625
Rebates for dual eligible and low-income subsidy population in Medicare Part D. Non-Interference. Implementation of the 21st Century Cures Act (P.L.114-255). ADUFA Reauthorization. Part D coverage gap and the Medicare reimbursement of biosimilars; H.R.1892, Bipartisan Budget Act of 2018 (P.L.115-123); H.R.1625, Consolidated Appropriations Act, 2018 (P.L.115-141).
Client expense: — · Firm income: $50,000
Matched citations: H.R.1892
Foreign Investment Risk Review Modernization Act of 2017
2018 · first_quarter · Firm: THORN RUN PARTNERS
Legislation related to CFIUS and FARA including issues related to critical technologies and export controls; S.2098/H.R.4311, Foreign Investment Risk Review Modernization Act of 2017; S.2482, Foreign Agents Registration Amendments Act of 2018.
Client expense: — · Firm income: $50,000
Matched citations: H.R.4311
Foreign Investment Risk Review Modernization Act of 2018
2018 · first_quarter · Firm: THORN RUN PARTNERS
Legislation related to CFIUS and FARA including issues related to critical technologies and export controls; S.2098/H.R.4311, Foreign Investment Risk Review Modernization Act of 2017; S.2482, Foreign Agents Registration Amendments Act of 2018.
Client expense: — · Firm income: $50,000
Matched citations: S.2098
Foreign Agents Registration Amendments Act of 2018
2018 · first_quarter · Firm: THORN RUN PARTNERS
Legislation related to CFIUS and FARA including issues related to critical technologies and export controls; S.2098/H.R.4311, Foreign Investment Risk Review Modernization Act of 2017; S.2482, Foreign Agents Registration Amendments Act of 2018.
Client expense: — · Firm income: $50,000
Matched citations: S.2482
American Health Care Act of 2017
2017 · fourth_quarter · Firm: THORN RUN PARTNERS
H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017. Cost Sharing (Preserving Access to Medicines). Healthcare Exchanges. Average Sales Price. Reimbursements. Children's Health Insurance Program (CHIP). Brand safety and security.
Client expense: — · Firm income: $50,000
Matched citations: H.R.1628
American Health Care Act of 2017
2017 · third_quarter · Firm: THORN RUN PARTNERS
H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017. H.R.2430/S.934, FDA Reauthorization Act of 2017 (P.L.115-52) Cost Sharing (Preserving Access to Medicines). Healthcare Exchanges. Average Sales Price. Reimbursements. Children's Health Insurance Program (CHIP). Brand safety and security.
Client expense: — · Firm income: $50,000
Matched citations: H.R.1628
FDA Reauthorization Act of 2017
2017 · third_quarter · Firm: THORN RUN PARTNERS
H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017. H.R.2430/S.934, FDA Reauthorization Act of 2017 (P.L.115-52) Cost Sharing (Preserving Access to Medicines). Healthcare Exchanges. Average Sales Price. Reimbursements. Children's Health Insurance Program (CHIP). Brand safety and security.
Client expense: — · Firm income: $50,000
Matched citations: H.R.2430
H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017. H.R.2430/S.934, FDA Reauthorization Act of 2017 (P.L.115-52) Cost Sharing (Preserving Access to Medicines). Healthcare Exchanges. Average Sales Price. Reimbursements. Children's Health Insurance Program (CHIP). Brand safety and security.
Client expense: — · Firm income: $50,000
Matched citations: S.934
STOP Act of 2017
2017 · third_quarter · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Synthetics Trafficking and Overdose Prevention Act of 2017 (S.372/HR 1057)
Client expense: — · Firm income: $40,000
Matched citations: HR 1057
STOP Act of 2017
2017 · third_quarter · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Synthetics Trafficking and Overdose Prevention Act of 2017 (S.372/HR 1057)
Client expense: — · Firm income: $40,000
Matched citations: S.372
FDA Reauthorization Act of 2017
2017 · third_quarter · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Diabetes and cardiovascular health awareness, drug importation, pharmaceutical pricing, FDA regulation of animal drugs/compounding of animal drugs, S.934, Food and Drug Administration Reauthorization Act
Client expense: — · Firm income: $40,000
Matched citations: S.934
American Health Care Act of 2017
2017 · second_quarter · Firm: THORN RUN PARTNERS
H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017. Cost Sharing (Preserving Access to Medicines). Healthcare Exchanges. Average Sales Price. Reimbursements. Children's Health Insurance Program (CHIP). Brand safety and security.
Client expense: — · Firm income: $50,000
Matched citations: H.R.1628
FDA Reauthorization Act of 2017
2017 · second_quarter · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to drug importation, counterfeiting, biosimilar reimbursement, S. 934, FDA regulation of animal drugs and Synthetics Trafficking and Overdose Prevention Act of 2017.
Client expense: — · Firm income: $40,000
Matched citations: S. 934
Source: Senate LDA